{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:32:48Z","timestamp":1794267168459,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpba.2025.117078","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:00:26Z","timestamp":1753286426000},"page":"117078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["LC-MS\/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib"],"prefix":"10.1016","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-9261","authenticated-orcid":false,"given":"Marinda","family":"Meertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Dani\u00eblle","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0118-561X","authenticated-orcid":false,"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jpba.2025.117078_bib1","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120858","article-title":"Personalized therapy for lung cancer: striking a moving target","volume":"3","author":"Pakkala","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jpba.2025.117078_bib2","first-page":"JCO2400581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.jpba.2025.117078_bib3","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"10026","key":"10.1016\/j.jpba.2025.117078_bib4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Biomarkers France c. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jpba.2025.117078_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.jpba.2025.117078_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"trial i. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.jpba.2025.117078_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in trk fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.jpba.2025.117078_bib8","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.jpba.2025.117078_bib9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jpba.2025.117078_bib10","unstructured":"Food and Drug Administration. Center for Drug Evaluation and Research Entrectinib Clinical Pharmacology and Biopharmaceutics Review 2016 [cited 2024 1st of August]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.117078_bib11","unstructured":"Food and Drug Administration. Center for Drug Evaluation and Research Pralsetinib Clinical Pharmacology and Biopharmaceutics Review 2019 [Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213721Orig1s000MultidisciplineR.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.117078_bib12","unstructured":"Food and Drug Administration. Center for Drug Evaluation and Research Selpercatinib Clinical Pharmacology and Biopharmaceutics Review 2019 [cited 2024 1st of August]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213246Orig1s000MultidisciplineR.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.117078_bib13","unstructured":"Food and Drug Administration. Center for Drug Evaluation and Research Sotorasib Clinical Pharmacology and Biopharmaceutics Review 2020 [cited 2024 1st of August]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214665Orig1s000MultidisciplineR.pdf\u3009."},{"issue":"10","key":"10.1016\/j.jpba.2025.117078_bib14","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","article-title":"Therapeutic drug monitoring of kinase inhibitors in oncology","volume":"62","author":"van der Kleij","year":"2023","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jpba.2025.117078_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-024-04640-0","article-title":"Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data","author":"Lau","year":"2024","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.jpba.2025.117078_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.670862","article-title":"A review of CYP3A drug-drug interaction studies: practical guidelines for patients using targeted oral anticancer drugs","volume":"12","author":"Molenaar-Kuijsten","year":"2021","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.jpba.2025.117078_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s40001-023-01172-w","article-title":"First reported double drug-drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature","volume":"28","author":"Fort-Casamartina","year":"2023","journal-title":"Eur. J. Med Res"},{"issue":"11","key":"10.1016\/j.jpba.2025.117078_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5720","article-title":"Development and validation of an HPLC-MS\/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices","volume":"37","author":"Retmana","year":"2023","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2025.117078_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115612","article-title":"Validated LC-MS\/MS method for simultaneous quantification of KRAS(G12C) inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study","volume":"235","author":"Retmana","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117078_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122131","article-title":"Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry","volume":"1147","author":"Senturk","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2025.117078_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jchromb.2018.10.023","article-title":"Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry","volume":"1102-1103","author":"Sparidans","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2025.117078_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jchromb.2018.03.014","article-title":"Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry","volume":"1083","author":"Spatari","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.jpba.2025.117078_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4467","article-title":"Quantification and pharmacokinetic study of entrectinib in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry","volume":"33","author":"Wang","year":"2019","journal-title":"Biomed. Chromatogr."},{"issue":"5","key":"10.1016\/j.jpba.2025.117078_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4155\/bio-2020-0011","article-title":"Quantitation of capmatinib, a mesenchymal-epithelial transition factor inhibitor by UPLC-MS\/MS in rat plasma and its application to a pharmacokinetic study","volume":"12","author":"Zhou","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2025.117078_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123918","article-title":"Validated extended multiplexed LC-MS\/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs","volume":"1231","author":"Kruithof","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"5","key":"10.1016\/j.jpba.2025.117078_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5610","article-title":"Development of HPLC-MS\/MS assay for quantitation of ensartinib in human plasma and its application to a pharmacokinetics study in Chinese patients","volume":"37","author":"Li","year":"2023","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2025.117078_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105074","article-title":"Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis","volume":"102","author":"Ernst","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jpba.2025.117078_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4623","article-title":"Bioanalytical LC-MS\/MS validation of therapeutic drug monitoring assays in oncology","volume":"34","author":"van Nuland","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2025.117078_bib29","unstructured":"European Medicines Agency. ICH guideline M10 on bioanalytical method validation and study sample analysis. [Internet]. 2022 [30 March 2023]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation\u3009."},{"issue":"12","key":"10.1016\/j.jpba.2025.117078_bib30","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.21037\/jtd-22-1606","article-title":"Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial","volume":"14","author":"Ma","year":"2022","journal-title":"J. Thorac. Dis."},{"issue":"3","key":"10.1016\/j.jpba.2025.117078_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10637-020-01047-5","article-title":"Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors","volume":"39","author":"Meneses-Lorente","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.jpba.2025.117078_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2019.01.001","article-title":"Development and validation of an UPLC-MS\/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology","volume":"1106-1107","author":"van Nuland","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2025.117078_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121925","article-title":"Development and validation of an integrated LC-MS\/MS assay for therapeutic drug monitoring of five PARP-inhibitors","volume":"1138","author":"Bruin","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T02:36:43Z","timestamp":1757126203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525004194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":33,"alternative-id":["S0731708525004194"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117078","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS\/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117078"}}